Print ISSN:-2581-5555
Online ISSN:-2456-9542
CODEN : IIJCDU
Original Article
Author Details :
Volume : 8, Issue : 2, Year : 2023
Article Page : 112-117
https://doi.org/10.18231/j.ijcaap.2023.019
Abstract
Background: The number of times a publication or an individual author has been discussed in the scientific community is a common metric for measuring their impact. The goal of the bibliometric study was to look at the maximum cited articles in the area of "pancreatic cancer, nanoparticles, targeted ligand, binding, drug delivery and treatment.".
Materials and Methods: The database SCOPUS was used to conduct a computerised literature search. The top 100 articles with the most citations were chosen and studied further
Results: There were 298 citations in the most cited article, with an average of 62 citations per publication. These highly cited publications appeared in 33 journals, with the Journal of Controlled Release leading the pack (27 articles). The United States contributed 53 articles, which originated from 19 different countries. These 100 citations were provided by 85 institutions, with the “Department of Chemical and Biomolecular Engineering” leading the way (4).
Conclusions: The investigation of the top highly cited articles concedes for recognizing significant advances in pancreatic cancer targeted drug delivery study and gives a historical perspective on the advancement of this speciality of cancer research.
Keywords: Pancreatic Cancer, nanoparticles, Targeted Drug delivery, Global publications, Bibliometric analysis, TopCitations
How to cite : Sharma N, Arora V, Joshi G, Prajapati B G, Parihar A, Role of nanoparticles in pancreatic drug delivery: Including a bibliography on Targeted drug delivery. IP Int J Compr Adv Pharmacol 2023;8(2):112-117
This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.